Skip to main content
Erschienen in: Acta Neurochirurgica 11/2015

01.11.2015 | Clinical Article - Brain Tumors

Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2

verfasst von: Huan Li, Shu-Yu Hao, Liang Wang, Da Li, Zhen Wu, Li-Wei Zhang, Jun-Ting Zhang

Erschienen in: Acta Neurochirurgica | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Neurofibromatosis type 2 (NF2) is a devastating disease with no well-accepted management guidelines. Better understanding of the disease process provides the basis for how or when to initiate treatment. Only few studies have addressed the factors influencing the growth rate of NF2-related vestibular schwannomas (VSs), and these studies have reported variable results. This study aimed to assess the clinical factors influencing the growth rate of NF2-related VSs.

Methods

The medical records of 66 patients (totalling 74 VSs) were retrospectively analysed. The tumours were measured according to a two-component box model. The tumour growth rate was estimated by linear regression analysis of the changes in VS volumes over time. The clinical characteristics of all the patients were recorded. The relationship between the tumour growth rate and clinical factors were analysed. Linear regression, Pearson’s correlation and Student’s t-test were conducted using the SPSS 19.0 statistical package.

Results

The median follow-up duration was 4.9 years. The VSs growth rate was highly correlated with the initial VS volume (r = 0.97, p < 0.01). However, it was inversely correlated with the age at symptom onset (r = −0.41, p < 0.01). The average VS growth rate in patients with spinal tumours was 13.18 cm3/year compared with 0.19 cm3/year in patients without spinal tumours (p < 0.01). The VS growth rate in patients who had resection of a contralateral VS was slightly higher than that of patients with untreated VSs (p < 0.01). Other factors including sex, vestibular symptom, presence of other cranial schwannomas, family history and dermal abnormalities did not affect the VS growth rate.

Conclusions

The potential clinical factors influencing the VS growth rate are the age at symptom onset, initial tumour volume and presence of spinal tumours. Surgical resection of VSs might accelerate the growth rate of contralateral tumours. The effects of these factors require further experimental confirmation.
Literatur
1.
Zurück zum Zitat Abaza MM, Makariou E, Armstrong M, Lalwani AK (1996) Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 106:694–699CrossRefPubMed Abaza MM, Makariou E, Armstrong M, Lalwani AK (1996) Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 106:694–699CrossRefPubMed
2.
Zurück zum Zitat Aboukais R, Baroncini M, Zairi F, Bonne NX, Schapira S, Vincent C, Lejeune JP (2013) Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien) 155:771–777CrossRef Aboukais R, Baroncini M, Zairi F, Bonne NX, Schapira S, Vincent C, Lejeune JP (2013) Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien) 155:771–777CrossRef
3.
Zurück zum Zitat Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986CrossRefPubMed Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986CrossRefPubMed
4.
Zurück zum Zitat Baser ME, Makariou EV, Parry DM (2002) Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217–222CrossRefPubMed Baser ME, Makariou EV, Parry DM (2002) Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217–222CrossRefPubMed
5.
Zurück zum Zitat Baser ME, Mautner VF, Parry DM, Evans DG (2005) Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. J Med Genet 42:903–906PubMedCentralCrossRefPubMed Baser ME, Mautner VF, Parry DM, Evans DG (2005) Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. J Med Genet 42:903–906PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A:24–41PubMedCentralCrossRefPubMed Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A:24–41PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Choi JW, Lee Jy F, Phi JH, Phi Jh F, Wang K-C, Wang Kc F, Chung H-T, Chung H, Paek SH F, Paek Sh F, Kim DG (2014) Clinical course of vestibular schwannoma in pediatric neurofibromatosis type 2. J Neurosurg Pediatr 13(6):650–657CrossRefPubMed Choi JW, Lee Jy F, Phi JH, Phi Jh F, Wang K-C, Wang Kc F, Chung H-T, Chung H, Paek SH F, Paek Sh F, Kim DG (2014) Clinical course of vestibular schwannoma in pediatric neurofibromatosis type 2. J Neurosurg Pediatr 13(6):650–657CrossRefPubMed
8.
Zurück zum Zitat Dang M, Modi J, Roberts M, Chan C, Mitchell JR (2013) Validation study of a fast, accurate, and precise brain tumor volume measurement. Comput Methods Prog Biomed 111:480–487CrossRef Dang M, Modi J, Roberts M, Chan C, Mitchell JR (2013) Validation study of a fast, accurate, and precise brain tumor volume measurement. Comput Methods Prog Biomed 111:480–487CrossRef
9.
Zurück zum Zitat Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, Lonser RR, Asthagiri AR (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 117:109–117CrossRefPubMed Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, Lonser RR, Asthagiri AR (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 117:109–117CrossRefPubMed
10.
Zurück zum Zitat Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A (2005) Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2:574–579CrossRefPubMed Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A (2005) Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2:574–579CrossRefPubMed
12.
Zurück zum Zitat Evans DG, Baser ME, O’Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5–12CrossRefPubMed Evans DG, Baser ME, O’Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R (2005) Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 19:5–12CrossRefPubMed
13.
Zurück zum Zitat Evans DG, Bowers N, Huson SM, Wallace A (2013) Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity. Clin Genet 83:594–595CrossRefPubMed Evans DG, Bowers N, Huson SM, Wallace A (2013) Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity. Clin Genet 83:594–595CrossRefPubMed
14.
Zurück zum Zitat Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom II. Guidelines for genetic counselling. J Med Genet 29:847–852PubMedCentralCrossRefPubMed Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom II. Guidelines for genetic counselling. J Med Genet 29:847–852PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846PubMedCentralCrossRefPubMed Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M (2009) Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 15:5032–5039PubMedCentralCrossRefPubMed Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M (2009) Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 15:5032–5039PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Evans DG, Wallace A (2009) An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). J Med Genet 46:792CrossRefPubMed Evans DG, Wallace A (2009) An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2). J Med Genet 46:792CrossRefPubMed
18.
Zurück zum Zitat Fukuda M, Oishi M, Hiraishi T, Natsumeda M, Fujii Y (2011) Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection. J Neurosurg 114:1224–1231PubMed Fukuda M, Oishi M, Hiraishi T, Natsumeda M, Fujii Y (2011) Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection. J Neurosurg 114:1224–1231PubMed
19.
Zurück zum Zitat Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, Kalamarides M (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14:1090–1096PubMedCentralCrossRefPubMed Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, Kalamarides M (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14:1090–1096PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Ito E, Saito K, Yatsuya H, Nagatani T, Otsuka G (2009) Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. Neurosurg Rev 32:425–433CrossRefPubMed Ito E, Saito K, Yatsuya H, Nagatani T, Otsuka G (2009) Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. Neurosurg Rev 32:425–433CrossRefPubMed
21.
Zurück zum Zitat Jalayer Naderi N, Tirgari F, Esmaili F, Paktinat F, Keshavarz Z (2012) Vascular endothelial growth factor and ki-67 antigen expression in relation to age and gender in oral squamous cell carcinoma. J Dent Res Dent Clin Dent Prospects 6:103–107PubMedCentralPubMed Jalayer Naderi N, Tirgari F, Esmaili F, Paktinat F, Keshavarz Z (2012) Vascular endothelial growth factor and ki-67 antigen expression in relation to age and gender in oral squamous cell carcinoma. J Dent Res Dent Clin Dent Prospects 6:103–107PubMedCentralPubMed
22.
Zurück zum Zitat Lassaletta L, Torres-Martin M, Pena-Granero C, Roda JM, Santa-Cruz-Ruiz S, Castresana JS, Gavilan J, Rey JA (2013) NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications. Otol Neurotol 34:1355–1361CrossRefPubMed Lassaletta L, Torres-Martin M, Pena-Granero C, Roda JM, Santa-Cruz-Ruiz S, Castresana JS, Gavilan J, Rey JA (2013) NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications. Otol Neurotol 34:1355–1361CrossRefPubMed
23.
Zurück zum Zitat Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460–468, discussion 468–470 PubMed Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD (2007) Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:460–468, discussion 468–470 PubMed
24.
Zurück zum Zitat Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96:223–228CrossRefPubMed Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96:223–228CrossRefPubMed
25.
Zurück zum Zitat Nutik SL, Babb MJ (2001) Determinants of tumor size and growth in vestibular schwannomas. J Neurosurg 94:922–926CrossRefPubMed Nutik SL, Babb MJ (2001) Determinants of tumor size and growth in vestibular schwannomas. J Neurosurg 94:922–926CrossRefPubMed
26.
Zurück zum Zitat Odat HA, Piccirillo E, Sequino G, Taibah A, Sanna M (2011) Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol 32:1163–1170CrossRefPubMed Odat HA, Piccirillo E, Sequino G, Taibah A, Sanna M (2011) Management strategy of vestibular schwannoma in neurofibromatosis type 2. Otol Neurotol 32:1163–1170CrossRefPubMed
27.
Zurück zum Zitat Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913, discussion 914; quiz 914 CrossRefPubMed Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913, discussion 914; quiz 914 CrossRefPubMed
28.
Zurück zum Zitat Peyre M, Goutagny S, Imbeaud S, Bozorg-Grayeli A, Felce M, Sterkers O, Kalamarides M (2011) Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro Oncol 13:1125–1132PubMedCentralCrossRefPubMed Peyre M, Goutagny S, Imbeaud S, Bozorg-Grayeli A, Felce M, Sterkers O, Kalamarides M (2011) Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro Oncol 13:1125–1132PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Phi JH, Kim DG, Chung HT, Lee J, Paek SH, Jung HW (2009) Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 115:390–398CrossRefPubMed Phi JH, Kim DG, Chung HT, Lee J, Paek SH, Jung HW (2009) Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 115:390–398CrossRefPubMed
30.
Zurück zum Zitat Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–1052CrossRefPubMed Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–1052CrossRefPubMed
31.
Zurück zum Zitat Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35:e50–56CrossRefPubMed Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35:e50–56CrossRefPubMed
32.
Zurück zum Zitat Plotkin SR, O’Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP (2011) Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 14:543–547CrossRefPubMed Plotkin SR, O’Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP (2011) Spinal ependymomas in neurofibromatosis type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 14:543–547CrossRefPubMed
33.
Zurück zum Zitat Rosenberg SI, Silverstein H, Gordon MA, Flanzer JM, Willcox TO, Silverstein J (1993) A comparison of growth rates of acoustic neuromas: nonsurgical patients vs. Subtotal resection. Otolaryngol Head Neck Surg 109:482–487PubMed Rosenberg SI, Silverstein H, Gordon MA, Flanzer JM, Willcox TO, Silverstein J (1993) A comparison of growth rates of acoustic neuromas: nonsurgical patients vs. Subtotal resection. Otolaryngol Head Neck Surg 109:482–487PubMed
34.
Zurück zum Zitat Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J (2003) Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 22:30–34PubMed Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J (2003) Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 22:30–34PubMed
35.
Zurück zum Zitat Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M (2004) Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25:811–817CrossRefPubMed Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M (2004) Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25:811–817CrossRefPubMed
36.
Zurück zum Zitat Suryanarayanan R, Ramsden RT, Saeed SR, Aggarwal R, King AT, Rutherford SA, Evans DG, Gillespie JE (2010) Vestibular schwannoma: role of conservative management. J Laryngol Otol 124:251–257CrossRefPubMed Suryanarayanan R, Ramsden RT, Saeed SR, Aggarwal R, King AT, Rutherford SA, Evans DG, Gillespie JE (2010) Vestibular schwannoma: role of conservative management. J Laryngol Otol 124:251–257CrossRefPubMed
37.
Zurück zum Zitat Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMed Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMed
38.
Zurück zum Zitat Torres-Martín M, Martinez-Glez V, Peña-Granero C, Lassaletta L, Isla A, de Campos JM, Pinto GR, Burbano RR, Meléndez B, Castresana JS, Rey JA (2013) Expression analysis of tumor-related genes involved in critical regulatory pathways in schwannomas. Clin Transl Oncol 15:409–411CrossRefPubMed Torres-Martín M, Martinez-Glez V, Peña-Granero C, Lassaletta L, Isla A, de Campos JM, Pinto GR, Burbano RR, Meléndez B, Castresana JS, Rey JA (2013) Expression analysis of tumor-related genes involved in critical regulatory pathways in schwannomas. Clin Transl Oncol 15:409–411CrossRefPubMed
39.
Zurück zum Zitat Tysome JR, Macfarlane R, Durie-Gair J, Donnelly N, Mannion R, Knight R, Harris F, Vanat ZH, Tam YC, Burton K, Hensiek A, Raymond FL, Moffat DA, Axon PR (2012) Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol 33:466–472CrossRefPubMed Tysome JR, Macfarlane R, Durie-Gair J, Donnelly N, Mannion R, Knight R, Harris F, Vanat ZH, Tam YC, Burton K, Hensiek A, Raymond FL, Moffat DA, Axon PR (2012) Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol 33:466–472CrossRefPubMed
Metadaten
Titel
Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2
verfasst von
Huan Li
Shu-Yu Hao
Liang Wang
Da Li
Zhen Wu
Li-Wei Zhang
Jun-Ting Zhang
Publikationsdatum
01.11.2015
Verlag
Springer Vienna
Erschienen in
Acta Neurochirurgica / Ausgabe 11/2015
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-015-2542-1

Weitere Artikel der Ausgabe 11/2015

Acta Neurochirurgica 11/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.